Metronomics Global Health Initiative

International Symposium of Metronomic Chemotherapy - Update on Multimodality Mechanisms including Immunotherapeutic Aspects

2017-02-10T11:13:27Z

We are delighted to announce that the International Symposium of Metronomic Chemotherapy - Update on Multimodality Mechanisms including Immunotherapeutic Aspects will take place next March in Tapei. The meeting is being organized by Kelvin K. Tsai, MD, PhD, Associate Investigator and Attending Physician
Laboratories for Tumor Aggressiveness and Stemness, National Institute of Cancer Research, National Health Research Institutes and Associate Professor and Principal Investigator, Laboratories of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan

International Symposium of Metronomic Chemotherapy - Update on Multimodality Mechanisms including Immunotherapeutic Aspects

Date: March 11, 2017 (Saturday)
Venue: Taipei Medical University
Sponsor: Taipei Medical University, National Health Research Institutes, Ministry of Science and Technology
Organizer: Taipei Medical University

Preliminary PROGRAM

09:00-09:30 Registration

Opening Remarks

09:30-09:40 Dr. Yun Yen President, Taipei Medical University

09:40-09:50 Dr. Chao-Ching Huang Dean, College of Medicine, Taipei Medical University

Keynote speech
09:50-10:50 Promise of Metronomic Chemotherapy Revealed in Preclinical Models of Advanced Metastatic Disease Dr. Robert S. Kerbel
Professor of Laboratory Medicine and Pathobiology, University of Toronto
Senior Scientist, Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Canada

10:50-11:10 Coffee Break

Session Chairman Dr. Li-Tzong Chen Director, National Institute of Cancer Research, National Health Research Institutes

11:10-11:40 Metronomic Chemotherapy Tempers the Stromal Response to Enhance Anti-tumor Efficacy Dr. Kelvin K. Tsai
Associate Professor, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan

11:40-12:10
Metronomic Chemotherapy and Checkpoint Inhibitors in Breast Cancer and Lymphoma Dr. Francesco Bertolini
Director, Laboratory Division of Hematology/Oncology, European Institute of Oncology, Milan, Italy

12:10-13:10 Lunch Break

Session Chairman Dr. Robert S. Kerbel
13:10-13:55 The Double Edged Sword of Cancer Therapy
Dr. Yuval Shaked Associate Professor, Vice Dean of Research, Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

13:55-14:40 TBD
Dr. Nicolas Andre
Associate Professor Service d'Hématologie et Oncologie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, and Metronomics Global Health Initiative, Marseille, France

14:40-15:00 Coffee Break

Session Chairman Dr. Gi-Shih Lien Superintendent, Taipei Medical University Wan Fang Hospital, Taiwan
15:00-15:45 TBD
15:45-16:30 TBD
16:30-17:15 TBD

Closing Remarks

1st LATIN AMERICAN MEETING IN METRONOMIC CHEMOTHERAPY AND DRUG REPOSITIONING IN ONCOLOGY

2016-05-04T13:26:00Z

The 1st LATIN AMERICAN MEETING IN METRONOMIC CHEMOTHERAPY AND DRUG REPOSITIONING IN ONCOLOGY will take place in ROSARIO, ARGENTINA, from MAY 27 to 28, 2016.

PRESIDENT
O. Graciela Scharovsky

ORGANISING COMMITTEE
Viviana R. Rozados (Chairperson)
Herman A. Perroud
María José Rico
Mauricio Menacho Máquez
Leandro E. Mainetti

SCIENTIFIC COMMITTEE
O. Graciela Scharovsky (Argentine)
Viviana R. Rozados (Argentine)
Carlos M. Alasino (Argentine)
Nicolas André (France)
Jaume Mora Graupera (Spain)

INVITED LECTURERNICOLAS ANDRÉ- Hopital pour Enfants de la Timone- Marseille, France; Metronomic Global Health Initiative

INVITED SPEAKERS
JAUME MORA GRAUPERA (Barcelona, Spain)
NORMA ESTHELA LLAMAS PEREGRINA (Mexico)
WENDY GÓMEZ GARCÍA (Dominican Republic)
HERMAN PERROUD (Argentine)
CARLOS M. ALASINO (Argentine)
VIVIANA R. ROZADOS (Argentine)
MARÍA JOSÉ RICO (Argentine)
MAURICIO MENACHO MÁRQUEZ (Argentine)
LEANDRO MAINETTI (Argentine)
PAULA SCHAIQUEVICH (Argentine)
ANDREZA ALMEIDA SENERCHIA (Brasil)
OSCAR ARRIETA (Mexico)
MILENA VILLARROEL (Chile)
LAURO GREGIANIN (Brasil)
ADRIANA ROSE (Argentine)
SIDNEI EPELMAN (Brasil)

PROGRAMMEOPENING CEREMONY
O.G. SCHAROVSKY - Welcome and introduction

OPENING LECTURE
N. ANDRÉ - Metronomic chemotherapy. MGHI and its proposal for low and middle income countries

SESSION 1: PRE-CLINIC EXPERIENCE
VIVIANA R. ROZADOS - Metronomic chemotherapy for lymphomas and sarcomas
LEANDRO E. MAINETTI - Metronomic chemotherapy with cyclophosphamide plus celecoxib or doxorubicin, for mammary adenocarcinomas.
MAURICIO MENACHO MÁRQUEZ - Metronomic chemotherapy with metformin plus propranolol for mammary adenocarcinomas.
MARÍA J. RICO - Metronomic chemotherapy. Comparative efficacy of three combined treatments.
PAULA SCHAIQUEVICH - In vitro studies of chemotherapy agents for the treatment of retinoblastomas.

SESSION 2: CLINIC EXPERIENCE IN PEDIATRIC CANCER
WENDY GÓMEZ GARCÍA – Experience report: palliative care programme & metronomic chemotherapy in the Hemato-Oncology service in the Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic, from January 2012 to January 2015.
JAUME MORA GRAUPERA – Maintenance treatment for patients with high risk Ewing sarcoma.
MILENA VILLARROEL - Metronomic chemotherapy for Ewing Sarcoma. Theoretical bases for the GALOP Protocol.
LAURO GREGIANIN - Metronomic chemotherapy for localized Ewing Sarcoma. Results of the GALOP Protocol.
ADRIANA ROSE - Metronomic chemotherapy for metastatic Ewing Sarcoma. Results of the GALOP Protocol.
SIDNEI EPELMAN - The role of metronomic treatment in children and adolescents with brain tumor.
NORMA ESTHELA LLAMAS PEREGRINA – Spiritual and emotional impact of metronomic chemotherapy in the patient and the family.

SESSION 3: CLINIC EXPERIENCE IN ADULT CANCER
CARLOS M. ALASINO - Metronomic chemotherapy for advanced breast cancer patients. Clinical outcomes.
HERMAN A. PERROUD – Metronomic chemotherapy for advanced breast cancer patients. Biomarkers and quality of life.
ANDREZA ALMEIDA SENERCHIA - Results of metronomic therapy for osteosarcoma patients: a report from the Latin American osteosarcoma treatment group.
DANIEL ALONSO - Desmopressin as perioperative adjuvant and hemostatic agent in oncology

SUMMARY AND PERSPECTIVES : GUILLERMO CHANTADA

CONCLUDING REMARKS: O. GRACIELA SCHAROVSKY

the updated program can be find in the attached file

Metronomics@Mumbai 2016: M@M 2016

2016-01-28T14:40:00Z

Metronomics @ Mumbai 2016: M@M 2016

The Metronomics @ Mumbai-2016, will take place in the “happening” city of Mumbai on the occasion of the 5th Biennial “International Metronomic & Anti-Angiogenic Meeting” t from 6th to 8th May 2016.

Even after waging the “war against cancer” for years, most of the advanced cancers are still not curable. On top of that many of the new chemotherapeutic drugs or“targeted therapies”that are introduced in the market, give a small, if at all, benefit over the existing therapies and come at a veryhighprice! However, the expensive investigations,medicines & supportive care required to deliver aggressive chemotherapies, have made these modern therapies out of reach of most patients having cancer in Low & Middle Income Countries. Even oncologists in High Income Countrieshavestartedquestioningtheirutility. Thus,the most important challenge at present in oncology is not just finding cures for patients with cancer, but to develop affordable, cost-effective therapies. In this context, the silent revolution of “Metronomic” chemotherapies is slowly sweeping across the globe.
Metronomic Rescheduling of Anticancer Treatment (MSAT) has now grown beyond the anticipated scope of anti-angiogenic chemotherapy, with accumulating evidence demonstrating that these treatments may also act by stimulating an antitumor immune response and could ultimately lead to re-induction of tumor dormancy. The concept of MSAT is no longer a laboratory restricted idea. As of 2014, there are more than 150 registered clinical trials in various stages of development examining metronomic therapy and its efficacy. This reiterates the growing interest in this area of cancer directed therapy. What widens the reach of metronomic chemotherapy is its potential ability to be combined with conventional cytotoxic chemotherapy & newer targeted therapies.
The identification of potential biomarkers for stratification of patients and identifying responses to metronomic chemotherapy, evaluating new response criteria to metronomic chemotherapy, correctly elucidating individual tumor biology and their potential of response to MSAT, and achieving uniformity of administration and dosage with MSAT are some of the many questions that remain to be answered. There are multiple checkpoints before MSAT can be introduced into mainstream oncology practice and not simply considered as an investigative therapy that is essentially palliative in nature.

With this preamble, we at Tata Memorial Hospital, a premier oncology specialty hospital in Mumbai, invite you to be a part of M@M, a conference dedicated to covering all aspects of metronomic therapy, from its biology, approach, clinical practice, current trends and future prospects.

You can submit abstract for oral and/or poster presentation (see attached form for details).
If you work in the field of pediatric oncology, you might submit your work for the 2nd Barton Kamen-MGHI prize (see dedicated post or click here)

Present Challenges of Mathematics in Oncology and Biology of cancer

2015-11-20T11:38:00Z

PRESENT CHALLENGES OF MATHEMATICS IN ONCOLOGY AND BIOLOGY OF CANCER

Description
This workshop aims at bringing together specialists and young researchers from different mathematical backgrounds (modeling, numerical simulations and analysis) and working in the field of oncology. This workshop would follow two previous workshops successfully organized by the CIRM in 2009 and 2011. The interest of bringing closer the world of mathematicians, oncologists and biologists is getting more and more accepted and is a very promising way of setting trans-disciplinary collaborations. Important progresses have been achieved in the discipline of onco-mathematics in the last decade.
The congress will focus on five topics:
– Microtubules, migration and cancer
– Metronomic chemotherapy
– Cancer Stem cells, evolution of phenotype
– Biomarkers
– Imaging and cancer

Through these sessions, we will put in light how mathematical modeling can help oncologists in terms of prognostic, prediction and therapy scheduling. We want to gather international experts in these five area of research in order to exchange and intensify the relations between the mathematical pharmacologists and oncologists communities.

Organizing commitee
– Nicolas André (MCU-PH, Aix-Marseille University, Centre de Recherche en Oncobiologie et Oncopharmacologie, CRO2, INSERM UMR_S 911 and MGHI)
– Assia Benabdallah (PR, Aix-Marseille University, Institut de mathématique de Marseille, I2M CNRS, UMR 7373)
- Dominique Barbolosi (PR, Aix-Marseille University, CRO2)
– Assia Benabdallah (PR, Aix-Marseille University, I2M)
- Manuel Gonzalez-Burgos (PR, Universidad de Sevilla, Spain)
– Florence Hubert (MCF, Aix-Marseille University, I2M)

Scientific commitee
– F. Barlesi (PU-PH, Faculty of medecine, Aix-Marseille University, FRANCE)
– J. Clairambault (DR, INRIA Rocquencourt, Paris, FRANCE)
– E. Grenier (PR, ENS Lyon, FRANCE)
- S. Honoré (MCF-PH, Faculty of pharmacy, Aix-Marseille University, FRANCE)
– U. Ledzewicz (Southern Illinois University Edwardsville, USA)
– C. Meille (Roche industry, Bale, SWITZERLAND)

MGHI at the Conference of New Ideas in Cancer: Challenging dogmas—Tata Memorial Centre Platinum Jubilee

2015-10-21T10:56:03Z

Tata Memorial Centre, Mumbai is on the cusp of a momentous year, namely, the 75th year of its existence. The platinum jubilee conference will be devoted to challenging the current dogmas and to debate the ‘currently entrenched versus contrarian viewpoints' in cancer research and treatment. The conference will be held at the National Centre for Performing Arts in Mumbai and the iconic Taj Mahal Palace Hotel has agreed to be our official hospitality partners from the 26th to 28th of February 2016.

It is likely to be a landmark conference, the first of its kind. Indeed, the central idea for the conference came from surveying the current landscape of cancer research and treatment and the disappointments that it has brought us. The last decade has been particularly frustrating as we have realized that the hype generated from molecular and genetic ‘breakthroughs' are translating neither into a meaningful understanding of the malignant process nor to a clinically relevant relief to our patients. In our desperate quest to prove our scientific approach to be right, we are even modifying our time-tested methodologies of clinical research, and getting increasingly excited by meaningless gains of “progression free survival” by a few months. A 2%-3% improvement in overall survival has become the outer limit of our intellectual expectation.

The Platinum Jubilee conference will be devoted to challenging the current dogmas and to debate the ‘currently entrenched versus contrarian viewpoints' in cancer research and treatment. Key international speakers and participants will deliberate on these issues critically over 3 days of the conference on carefully chosen themes in the form of symposia, debates and special lectures. Some of the emerging messages may lead to potentially paradigm shifting approaches to how we perceive and treat cancer. We are sure that the conference will be an academic feast and would appeal to all scientists, clinicians and health care professional involved in researching and treating cancer.

The Lancet Oncology, the US NCI and AACR have agreed to be partners.

Nicolas ANDRE, from MGHI has been invited to talk about the mechanism of action of chemotherapy.

Lear more about the programm and faculty memebers by clicking here.

Program

A Basic and Translational science
• Has the molecular revolution reached the bedside?
• How much of genomic data has translated into clinical practice?
• Targeted therapy has failed our patients (debate)
• Precision medicine is an empty slogan (debate)

B New ideas in clinical oncology
• Therapeutic strategies to harness the peri-operative window
•Biological principles of metronomic therapy
•Targeting copper to treat breast cancer
•Novel PI3 kinase inhibitor: from bench to bedside

C therapy resistance
•Cancer as an infectious disease caused by dead-cell chromatin
•Clinical implications of apoptotic circulating tumour cells
•Is the metastatic tumour genetically and histologically similar to the primary?
•Dead cell chromatin, tumour heterogeneity and therapy resistance

D Cancer data analysis
•Omics and big data sets: out of control?
•How relevant are the randomized controlled clinical trials in clinical practice?

E Public health and cancer statistics
•Harms of cancer screening
•Holistic approach to cancer management and prevention
•Challenges of HPV vaccination

F The lure of technology
•Harnessing technology for cancer treatment, who benefits?
•The politics and economics of novel technologies
•Advanced technologies and global cancer outcome

G Hospital day oration and special lectures
•Technological challenge, stagnation and decline in the 21st century
•Cancer research in need of a scientific revolution
•Thinking Outside the Box in Cancer Research: Perspectives from the US NCI
•Fractal geometry in oncogenesis

H Top abstracts session

I Grand discussion
•A 90 minute session highlighting the key messages from various talks and discussions during the
conference and also deliberate a possible cancer agenda for the future. Discussants will include
senior faculty, a few key note speakers and international policy makers.

J Public forum on cancer
•A 2 hour interaction between top experts and the public

36th EORTC-PAMM 2015 : Time for paradigm shifts in oncology ?

2014-11-04T09:37:00Z

The 36th PAMM-EORTC Winter Meeting will take place in Marseille from 21/01/2015 to 24/01/2015.
It will focus on ground-breaking innovations in experimental and translational oncology. It is organized under the umbrella of European Organization for Treatment of Cancer (EORTC), to provide a unique opportunity for interdisciplinary and international exchange of ideas on implementing knowledge on optimizing cancer treatment. The conference will feature presentations from internationally recognized leaders in the field of experimental, translational and clinical oncology. Scientists, researchers, and experts in the field of experimental therapeutics will offer new insights and innovative approaches to treat cancer, along with keynote lectures, oral and poster presentations.

Beside scientific sessions and presentations, several social events such as gala dinner and traditional PAMM indoor football match will make the PAMM-2015 in Marseille a great opportunity for stretching your boundaries through extensive exchanges with peers and experts.

Local Organising Committee

– Dr J. Ciccolini, Marseille, PAMM Scientific Committee
– Pr G.J. Peters, Amsterdam, The Netherlands

PRELIMINARY PROGRAM

1. MODELING & SIMULATION IN ONCOLOGY

Developing mathematical support in oncology is a rising trend both at the bench and the bedside. This session will focus on the variety of models that can be used today to better understand cancer biology and to improve anticancer agents efficacy and clinical use, i.e., mechanistic and semi-mechanistic models, PBPK approaches, computational driven regimen, new PK/PD modeling tools, etc...

KEYWORDS: Computational Oncology - Modeling & Simulation - PK/PD

2. METRONOMIC CHEMOTHERAPY

Metronomics has been first introduced in paediatric oncology and is now also considered as an attractive option in a variety of settings in adults. Beside the reduction of drug-induced toxicities, novel mechanisms of action (i.e., anti-angiogenic or immunostimulating properties) have emerged from the use of low doses of anticancer drugs. This session will cover the achievements, current limits and expectancies of metronomic chemotherapy in cancer.

KEYWORDS: Metronomics - Paediatrics Oncology - Drug Repositionning

3. BIOGUIDED ONCOLOGY

Biomarker-based medicine has been now widely integrated in clinical practice in melanoma, colorectal, lung or breast cancers. Still, there is still a discrepancy between the plethora of putative markers constantly published and the number of validated tests actually reaching bedside applications. This session will cover the latest tools made available to screen patients, the latest markers emerging from molecular biology, and the latest clinical applications in pharmacogenetics and pharmacogenomics.

KEYWORDS: Precision medicine - Pharmacogenetics - Pharmacogenomics - Biomarker-based medicine

4. OMICS & IMAGING IN ONCOLOGY

Translational oncology has benefited from recent advances in the field of in vitro and in vivo imaging, plus the rise of -omics (e.g., metabolomics, proteomics, etc..). This technical session will present the latest tools and applications made available in experimental and translational oncology.

KEYWORDS: Metabolomics - Proteomics - Imaging - Experimental Therapeutics

5. NANOTECHNOLOGY & DRUG DELIVERY

Optimizing drug delivery of anticancer agents is an attractive strategy to optimize the efficacy/toxicity balance. This session will cover the latest advances in the field of medical chemistry applied to nanomedicine in oncology (i.e., conjugated drugs, nanoparticles, smart drugs).

KEYWORDS: Medicinal chemistry - Nanoparticles - Drug delivery

6. BIOTECHNOLOGIES & IMMUNOTHERAPY

Clinical oncology has benefited over the last decade of the rise of novel bioengineered entities. This session will cover the most recent advances beside monoclonal antibodies (i.e., peptibodies, nanobodies and other entities) that are now developed to adress novel targets, including to trigger immune response against cancer.

KEYWORDS: Biologics - Immunotherapy - Novel scafolds

CONFIRMED SPEAKERS

N. André, Marseille, FR
F. André, Villejuif, FR
F. Barlési, Marseille, FR
JP. Benoit, Tours, FR
S. Benzekry, Bordeaux, FR
R. Costello, Marseille, FR
P. Couvreur, Paris, FR
M. D'Incalzi, Milano, IT
D. Jodrell, Cambridge, UK
D. Lafitte, Marseille, FR
HL. Mc Leod, Tampa, USA
C. Meille, Basel, CH
G. Milano, Nice, FR
E. Pasquier, Randwick, AUS
GJ. Peters, Amsterdam, NL
Y. Shaked, Haïfa, IL
JF. Seitz, Marseille, FR
JC. Soria, Villejuif, FR
M. Ychou, Montpellier, FR
W. Zamboni, Chapel Hill, USA

learn more about it on the dedicated websitehere

4th Metronomic Chemotherapy Meeting-Milano 2014

2014-05-11T15:09:00Z

We are pleased to announce that the 4th Metronomic Chemotherapy Meeting will take place in Milano on the 24-25th June in the IFOM-IEO Campus, Milano, Italy.
The organisator is Pr Francesco Bertolini, Director of the Laboratory of Hematology/Oncology at the European Institute of Oncology in Milan and the Chairs and organizing committee will be composed of Francesco Bertolini, Marco Colleoni, Saverio Cinieri, Nicolas André and Yuval Shaked.
A specific website has been set for this event, where registration will be opened soon.

The program of the meeting will include preclinical, adult and pediatric oncology, low income country sessions.

The First Barton Kamen Prize will also be given during the meeting. To learn more about it click here

Abstract can be sumitted directly to francesco.bertolini@ieo.it. Full instructions for the abstract can be found here

New information such as dates, expected speakers, preliminary program will be regularly posted.

FINAL PROGRAM

June 24th

12.50-13.00 F. Bertolini - Welcome and introduction

session 1: The landscape of the field.

Chair: F. Bertolini and L. Hutchinson

13.00-13.30 R. S. Kerbel : Metronomic from 2000 to 2014

13.30-14.00 Y. Shaked - Preclinical new hypotheses

14.00-14.30 L. Hutchinson, editor of “Nature Reviews in Clinical Oncology”: Metronomic needs from the perspective of an editor

Session 2: breast cancer, pediatric cancer and models.

Chairs: M. Colleoni and N. Andrè

14.30-15.00 M. Colleoni - Clinical Overview on the metronomic experience in breast cancer

15.00-15.30 E. Munzone: Present and future trials in breast cancer

15.30-16.00 G. Curigliano: Metronomic chemotherapy for lymphangitic breast cancer

16.00-16.30 coffee break

16.30-17.00 G. Brandi – Metronomic chemotherapy for hepatocellular carcinomas

17.00-18.00 F. Berthold and J. Sterba : Pediatric metronomic therapy

18.00-18.30 U. Ledzewicz: Mathematical models for chemotherapy

18.30-19.00 Ugo Cavallaro: New Players and targets in Tumor Vasculature

19.00-19.30 Barton Kamen-MGHI Prize

June 25th

session 3: Biomarkers and repositioning.

Chair R. S. Kerbel and Y. Shaked

09.00-9.30 G. Bocci - Biomarkers for Metronomic chemotherapy

09.30-11.00 N. André-A.Eniu-S.Banavali - Metronomics and low/middle income countries

11.00 - 11.30 coffee break

11.30-12.00 E. Pasquier : Is drug repositioning metronomic?

12.00-12.30 F. Bertolini: Repositioning: Metronomic therapy beyond metronomic chemotherapy

12.30-13.30 Lunch

Session 4: More types of cancer and selected presentations.

Chair: S. Cinieri and S.Banavali

13.30-14.00 M. Villalba: tailored metronomic approaches for acute leukemia

14.00-14.40 N. Fazio and A. Berruti: Metronomic chemotherapy for endocrine and neuroendocrine tumors

14.40-17.00 Oral presentation session with 7 talks 15+5 min

17.00-17:30 Round table: where do we go from here. Questions and answers
R.S. Kerbel, F. Bertolini, M. Colleoni, S. Cinieri, N. Andrè, Y. Shaked. S. Banavali

17.30: Concluding remarks

Metronomics at the SAIC-SAFIS 2013 in Argentina

2013-11-17T09:42:00Z

MGHI will be present at the SAIC 2013 annual Meeting which will be held jointly with the Argentine Society of Physiology (SAFIS) and the Argentine Society of Experimental Pharmacology (SAFE).
Further information regarding the meeting are available soon here

Dr Nicolas ANDRE will give a lecture entitled " Metronomics: Combining scientific, medical and social innovation" which has been scheduled for Thursday, November 21th.

The full program can be find on the website in the attached document.

Pediatric Oncology Symposium in Brazil (INTCR-TUCCA-Consulat Général de France )

2013-03-02T14:04:00Z

En partenariat avec l'INCTR, le Consulat Général de France structure un symposium intitulé : O papel e a relevância da Quimioterapia Metronômica na Oncologia Pediátrica entre les centres de lutte contre le cancer du Brésil, de l'Amérique du sud et de la France. Le thème principal est le traitement métronomique et les agents biologiques en oncologie pédiatrique. Ce symposium vise à partager des expériences, et de mettre en place des projets collaboratifs entre les groupes groupes présent. Un workshop propose une discussion avec les centres partenariat et la SOBOPE (Société brésilienne d'oncologie pédiatrique).
Le symposium se déroulera les 23-24 mai 2013

Programme :

Le concept de la thérapie métronomique
La métronomique en pédiatrie
L'expérience des centres
La chimiothérapie métronomique : une proposition de coopération brésilienne.

Metronomic at 2013 WIN SYMPOSIUM

2013-01-03T15:44:52Z

It is our pleasure to announce that members of MGHI will give lectures at 2013 symposium that will take place in Paris on July 10-12 at Le Palais des Congrès, Porte Maillot, Paris, France. The overall theme will be the “From innovation to implementation of personalized cancer therapy”

Pr Shripad Banavali from the Tata Memorial Centre in Parel, Mumbai will give a lecture about the use of metronomics in clinical trials and daily care with special focus on patients living in Low Income Countries.

WIN Symposia traditionally offer a blend of academia and industry – pharma, biotech, diagnostic – to jointly address all aspects of personalized cancer medicine. WIN 2013 will bring additional stakeholders to the scene, in addition to those that drive technological innovations. Organizations in charge of the implementation of innovations in daily practice are encouraged to participate in this symposium. WIN 2013 is a must-attend for all stakeholders in personalized cancer medicine across the globe.

Additional information about the 2012 Symposium on the Consortium can be found website,HERE.